Drug intelligence / Profile preview

fentanyl + midazolam + succinylcholine

Development stage: Unknown
Lead developer: Janssen Pharmaceutica
Modality: Small Molecules
Administration: Intravenous, Intramuscular

Overview

This combination is used in medical settings to facilitate procedures such as intubation. **Fentanyl** is a potent opioid analgesic used for pain management and anesthesia. It reduces the hypertensive and tachycardic response to intubation[6]. **Midazolam** is a benzodiazepine used for sedation and anxiolysis. It can cause respiratory depression, especially when combined with opioids[3]. **Succinylcholine** is a depolarizing neuromuscular blocker that induces rapid muscle relaxation, making it ideal for rapid sequence intubation[1][4].

Targets

DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)GABRR (GABA-A receptor subunit rho)KOR (Kappa opioid receptor)Muscle-type nicotinic acetylcholine receptor

Beyond the preview

Go deeper on fentanyl + midazolam + succinylcholine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fentanyl + midazolam + succinylcholine.

Explore the full profile